Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batiraxcept + Paclitaxel in Recurrent High Grade Uterine Cancer
NCT05826015Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2024
- Primary completion
- Jun 2029
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 1, open-label, single-arm trial of batiraxcept in uterine cancer, sponsored by Washington University School of Medicine. Primary endpoint: Frequency and severity of treatment-emergent adverse events. Planned start Oct 2024; status: withdrawn.
02
Drugs
batiraxcept
03
Conditions
uterine cancer
Beyond the preview
Go deeper on NCT05826015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05826015.